Lymphoblastic T-cell lymphoma in mice is unaffected by Celecoxib as single agent or in combination with cyclophosphamide
2009 (English)In: Leukemia and Lymphoma, ISSN 1042-8194, Vol. 50, no 7, 1198-1203 p.Article in journal (Refereed) Published
Celecoxib, an inhibitor of cyclooxygenase-2, is a promising novel antitumor agent with pleitropic mechanisms of action. Whereas this drug induces growth arrest and apoptosis of B-lymphoma cells, its effect against aggressive T-cell neoplasms remains to be studied. We therefore evaluated Celecoxib therapy of immunocompetent mice transplanted with lymphoblastic T-cell lymphomas. Oral Celecoxib in clinically relevant and non-toxic doses did not affect the degree of hypersplenism or the number of viable lymphoma cells. The clinical deterioration of Celecoxib-treated mice was not different from untreated controls. The impact of adding Celecoxib (60 mg/kg) to cyclophosphamide (200 mg/kg x 1, i.p.) was assessed but showed no benefit compared to cyclophosphamide alone. Thus, Celecoxib lacks effect against lymphoblastic T-cell lymphoma in mice.
Place, publisher, year, edition, pages
2009. Vol. 50, no 7, 1198-1203 p.
T-cell lymphoma, mouse, prostaglandins, Celecoxib, chemotherapy
Cancer and Oncology
Research subject Oncology
IdentifiersURN: urn:nbn:se:umu:diva-35016DOI: 10.1080/10428190902946930PubMedID: 19557641OAI: oai:DiVA.org:umu-35016DiVA: diva2:328256